Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Ceritinib versus chemotherapie bij gevorderd ALK-positief NSCLC: ASCEND-4
mrt 2017 | Longoncologie